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Abstract 
Motivation: This work constructs a closed loop Bayesian Network framework for predictive medicine via integrative 
analysis of publicly available gene expression findings pertaining to various diseases. 
Results:  An  automated  pipeline  was  successfully  constructed.  Integrative  models  were  made  based  on  gene 
expression  data  obtained  from  GEO  experiments  relating  to  four  different  diseases  using  Bayesian  statistical 
methods.  Many  of  these  models  demonstrated  a  high  level  of  accuracy  and  predictive  ability.  The  approach 
described in this paper can be applied to any complex disorder and can include any number and type of genome-
scale studies.  
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1  Introduction 
In recent years, several genome-wide technologies have been developed. As the amount of publicly available genomic 
data increases, the necessity for varying bioinformatics methodologies to conduct relevant analysis also increases. 
Much has been written about the obstacles presented by translating discoveries made via genomic data to medicine 
[1-4]. In order to circumvent these obstacles, the discipline of translational informatics has emerged – a discipline 
that  focuses  on  the  development  of  analytic  and  interpretive  methods  to  evaluate  the  increasing  amounts  of 
biological data into diagnostics and therapeutics for the clinical environment [5]. Many researchers have used an 
integrative approach to isolate genes that are associated with certain diseases. For example, such research has been 
widely done with respect to type I diabetes and obesity [6, 7]. These studies, among others, have demonstrated the 
efficacy of utilizing data from several genetic and microarray studies. 
 
1.1 Gene Expression Omnibus 
The Gene Expression Omnibus (GEO) is a publicly accessible repository of genomic data [8]. This project was 
initiated in response to an increasing demand for a public database of high-throughput gene expression data. The 
GEO offers a flexible platform for submission and retrieval of heterogeneous data sets from high-throughput gene 
expression and genomic hybridization experiments.  
 
The GEO categorizes all user-submitted experiments into samples, series, and platforms, many of which are then 
manually curated into DataSet records [9]; in this study, all gene expression data was obtained from DataSets. 
 
1.2 Bayesian Networks and Multinets 
In  a  Bayesian  approach  to  statistical  analysis,  the  data  analysis  process  begins  with  an  already  established 
probability distribution, referred to as the prior distribution. This process consists of using previously obtained 
sample data to update the prior distribution into a posterior distribution. The basic tool for this process is the Bayes’ 
theorem [10-11]. 
 
When dealing with complex problems, graphical models can help break down the complex systems into simpler 
parts, allowing for the analysis of a single variable. A Bayesian network is a directed, acyclic graphical structure. A 
simple Bayesian network is depicted in Figure 1. 
 
 
Figure 1: Example of a Bayesian network. In this example, A is the founder; X, Y, and Z are the children of A; A 
and Y are the parents of Z.
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Bayesian networks, a class of multivariate probabilistic models, not only account for variability in biological system, 
but  also  can  incorporate  higher-order  epistatic  interactions  and  their  interplay  with  environmental  and  clinical 
factors [10]. The modular nature of Bayesian networks, combined with computationally efficient algorithms to learn 
their structure, makes them an ideal tool for analyzing complex biological system. Using Bayesian networks, we can 
decompose  a  complex  joint  distribution  of  variables.  This  property  allows  compact  factorization  of  complex 
distribution over a high-dimensional space, which, in turn, yields great advantage in “learning” and inference [10-
11]. 
 
In the research conducted prior to this work, a certain type of Bayesian model known as the Bayesian multinet was 
constructed for analysis of disease [12]. Rather than being a singly structured Bayesian network as described above 
and portrayed in Figure 1, a Bayesian multinet is a set of distinct yet related Bayesian networks [13]. In the multinet 
classifiers, the dataset is first partitioned by classes, and a single Bayesian network (here, a tree-augmented structure also known as 
TAN) is constructed on each partition [13-14]. Then the data is classified  to  the  class  that  maximizes  the  posterior 
probability. Compared to a simple network, the multinet aims to more precisely model underlying pattern of dependency (e.g. 
epistatic dependencies) between features as the structure of the classifier is not forced to be static across classes. Therefore, the 
main  difference  for  constructing  singly  structure  Bayesian  network  and  multinets  is  in  treating  the  samples 
considered in the trial. For constructing multinets we keep the samples of each GEO experiment separate and we 
integrate the information content of each experiment through Bayesian inference step. However, for constructing the 
singly structure Bayesian networks we considered union of normalized samples from each GEO experiment. 
 
The power of our method in integrating different GEO experiments is three-fold: (1) Merging controls in related experiments results 
in a larger number of control group, which in turn increases the power of association, (2) The common-feature Bayesian multinet is 
able to capture different underlying pattern of dependency across multiple experiments, (3) The feature-differentiated Bayesian multinet 
is capable of not only capturing different pattern of dependency, but also utilizing different sets of features across experiments. 
 
1.3 Goals of Research 
Several studies have been done that merge gene expression data from multiple experiments with respect to a single 
disease. Though some of these studies have indeed used an automated approach to such research, they have focused 
on single diseases or disorders.  
 
This study aims to construct an automated framework that allows for the integration of genome-wide expression 
data (using the GEO) in regard to any disease or disorder, while also creating a predictive model for disease-related 
phenotypes that illustrates the relationship between various genetic factors and pathways in order to aid future 
treatment and study of these diseases. 
 
1.4 Diseases 
For this paper, the following disorders were studied: Huntington’s Disease, Obesity, Leukemia, and Lymphoma. 
These four diseases were selected based on the number of their respective related experiments in the GEO. The four 
aforementioned diseases are prevalent and pressing: Huntington’s Disease is a neurodegenerative disease with a 
worldwide prevalence of five to ten cases per 100,000 persons, Leukemia and Lymphoma are common causes of 
cancer-related deaths, and Obesity is a quickly growing problem. Though meta-analytic studies have been done with 
respect to these diseases, none of them have been examined extensively in a predictive sense. 
 
2  Materials and Methods 
The flowchart presented in Figure 2 outlines the methods used in this study. In the subsequent sections we detail 
each module in this flowchart.  
 
2.1 Downloading experiments from the GEO and disease mapping 
In order to create a mapping of all GEO DataSet files to diseases, a process similar to a study conducted at the 
Stanford  University  School  of  Medicine  [5]  was  used.  Several  methods  were  presented  in  this  paper;  the 
GENOTEXT system [15, 16]
  was initially explored as a possibility for creating the DataSet-disease mappings. 
However, it was eventually decided that a related but simpler method would be used for the purposes of this study. 
97 
 
 
All available GEO DataSet files were downloaded and read in order to obtain relevant information. Each experiment 
was mapped to disease(s) using their corresponding PubMed identification numbers and Medical Subject Heading 
terms.  
2.2 Merging experiments and obtaining expression data 
After generating this list of diseases and their associated GEO DataSets, a program was written in R to merge the 
GEO experiments and obtain all relevant gene expression data. The user first selects the disease to consider (i.e., 
Lymphoma), and using the disease-DataSet mapping list, looks up the relevant DataSet file names. This list of 
DataSet file names is fed into the automated program, which generates the multinets.  
 
Firstly, of the DataSet experiments fed into the program, it was determined which of the experiments were deemed 
“interesting” – for instance, in order to be relevant to the purpose of this study, an experiment must contain data 
comparing control versus non-control subjects in a manner that relates to the phenotype associated with the disease. 
This was done by looking for specific keywords in the DataSets (see Figure 2). After obtaining all “interesting” 
experiments, these experiments must be merged in some way. As gene expression values are unit-less and relative, 
each experiment’s data must be normalized with respect to all other experiments; this was done by selecting one 
experiment  as  the  “reference”  experiment  and  adjusting  all  other  experiment’s  values  relative  to  the  reference 
experiment. Subsequently, all samples from all experiments were merged according to control versus non-control 
samples.  
 
The top differentially expressed genes were found for each experiment individually via a number of steps. Firstly, a 
linear model was fit to each gene by using the design matrix of the microarray experiment, with rows corresponding 
to arrays and columns to coefficients to be estimated. Using this linear model, moderated t-statistics were computed 
by empirical Bayes shrinkage of the standard error toward a common value. This method was used to rank genes in 
order of evidence for differential expression. Finally, a table of the top-ranked genes from the linear model fit was 
extracted [17]. In this work, several trials were conducted; each one included a different number of top-ranked genes 
that were extracted. The genes that were studied were the ones that intersected across all experiments. 
 
As a basis for comparison, several trials were conducted using only single experiments to construct the models. 
Within each individual experiment, all samples related to the control state were merged with one another, while all 
samples related to the disease state were also merged. These data were then used to construct a Bayesian network 
using TAN structure [13]. 
 
2.3 Constructing multinets and receiver operating characteristic (ROC) curves 
In order to construct multinet Bayesian networks we first partition the data according to the classes (experiments) 
they are coming from. Then for each class of data a regular Bayesian network is constructed. One may use any type 
of Bayesian inference algorithm for construction of these “sub-networks”. We used TAN structure [13-14] for inferring 
the structure and conditional probabilities of each sub-network.  The Bayesian multinet classifier was validated using 3-fold 
cross-validation. In this procedure the set of samples is divided into three subsets of equal size. In each iteration, two 
subsets were used to find a common-feature set and train the model; the final subset is used to test the model. This 
procedure,  known  as  external  cross  validation,  is  essential  in  correcting  for  the  bias  that  is  induced  in  cross-
validation through the feature selection. The AUROC was estimated by averaging the AUROCs across the three 
folds [18]. In essence, the samples are divided into ten approximately equally sized subsets. In repeated simulations, 
nine  of  these  subsets  are  used  for  training  and  the tenth  is  used  for  testing.  The  area  under  the  ROC  curve 
(AUROC) value of the multinet’s cross-validation procedure indicates the model’s accuracy. 
 
The Receiver Operating Characteristic (ROC) is a curve that relates the true positive to the false positive rate for 
different thresholds. The AUROC is a statistical measure of robustness; the closer the AUROC is to 1, the closer the 
true positive ration is to 1, and the more accurate the predictive model. AUROC is a more comprehensive statistical 
measure of robustness than just predictive accuracy [17]. 
3  Results 
Several trials were done with each disease, varying the number of top differentially expressed genes that were 
examined.  For  each  trial,  the  AUROC  values  were  observed  as  a  measure  of  accuracy.  AUROC  provides  an 
objective metric for quantifying predictor accuracy. An AUROC of 0.7 to 0.8 is considered “fair,” from 0.8 to 0.9 is 
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considered  “good”,  and  from  0.9  to  1.0  is  considered  “excellent”  [20].  For  each  trial  we  constructed  a  singly 
structured Bayesian network as well as a multinet Bayesian network. The overall procedure is outlined in Figure 2. 
The main difference for constructing singly structure Bayesian networks from multinets is in treating the samples 
considered in the trial. For constructing multinets we kept the samples of each GEO experiment separate and we 
combined  the  information  content  of  each  experiment  through  assignment  step  (i.e.  by  finding  the  maximum 
posterior probabilities induced on each sub-network, see section 2.3 for details). However, for constructing the 
singly structure Bayesian networks we considered union of normalized samples from each GEO experiment.  
 
 
Figure 2: Outline of the design pipeline for comparison of multinets and single nets. 
 
4  Discussion 
In  this  work  we  present  two  ways  to  integrate  the  information  contents  of  multiple  independent  experiments  for 
classification purposes. One approach is to construct multinet Bayesian networks, which constructs a network on each 
experiment and combine the results in assignment step, and the other way is to construct a single network on the union of 
samples from all experiments. While both methods can be used for integrating the information of multiple experiments, 
we found that generally multinets outperform singly structured networks.  
 
 
Furthermore, we found that often times the most prominent genes were not present among the very top proportion of 
differentially expressed genes for each individual GEO experiment, but rather more toward the middle of the spectrum. 
The bias can be one factor that results in spurious differentially expressed genes for each experiment. In this regard, if all 
the conditions of multiple experiments were the same, the common list of differentially expressed genes across multiple 
experiments that we are considering is more robust to false positives. However, the application of our framework goes 
even beyond considering multiple experiments carried-out under exactly the same conditions or for exactly the same 
phenotype.  Here in order to achieve to a general view of the phenotype, we can consider various experiments on 
different subtypes, outcomes, conditions, and even different tissues in a predictive setting. Therefore, the implicated 
Automatically generate mapping 
from experiments to diseases 
using Mesh terms for GEO 
experiments  
Select disease and filter 
related experiments to disease 
Use keywords (“control”, 
“normal”, “no cancer”, 
“healthy”, “uninfected”) to 
filter related experiments to 
get only experiments with two 
“disease states”: disease vs. 
control 
Normalize gene 
expressions of all 
arrays across 
experiments  
Merge all samples across 
experiments for disease 
vs. control 
 
Find “common” top 
differentially expressed genes 
(FDR<0.1) across each 
experiment in training data.  
Use identified genes 
to construct multi-
nets 
Keep samples of 
diseases separate and 
merge samples for 
controls 
Use identified genes 
to construct single-
net 
Find the AUROC on 
hold-out data (the fold 
that is test data) 
 
External CV: 
Split the data to 
three folds. Take 
two as training 
and hold-out 
one as test data 
Build the 
classifier  (multi-
net or single net) 
on the whole data 
by the same 
schemes from the 
highlighted area 
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genes are those that are presented in all considered aspect of the phenotype. These genes can be viewed as those genes 
that regardless of bias, subtypes, and conditions, are contributing to the phenotype.  
 
 
Disease 
 
Number of GEO 
Experiments 
% Top 
Genes 
Num. of 
Common Genes 
AUROC for 
each fold of 
CV 
Average 
AUROC 
 
Predictor 
Category 
Huntington's 
Disease multinet  4  15%  16 
0.857, 0.859, 
0.804  0.840 
 
Good 
Huntington's Disease 
single net  4  15%   
0.577, 0.610, 
0.588  0.592 
 
Poor 
Obesity  
multinet  12  35%  21 
0.840, 0.792, 
0.800  0.783 
 
Fair 
Obesity  
single net  12  35%   
0.568, 0.571, 
0.607  0.582 
 
Poor 
Leukemia  
multinet  12   25%  13 
0.796, 0.759, 
0.743  0.774 
 
Fair 
Leukemia  
single net  12   25%   
0.506, 0.538, 
0.561  0.535 
 
Poor 
Lymphoma  
multinet  6   15%  27 
0.763, 0.829, 
0.852  0.867 
 
Good 
Lymphoma  
single net  6   15%   
0.591, 0.640, 
0.566  0.599 
 
Poor 
 
Table  1:  Summary  of  results  for  each  disease.  The  second  column  displays  the  number  of  GEO  experiments 
considered for constructing the multinet and single nets; the third column shows the percentage of top differentially 
expressed genes that were taken from each experiment; and the fourth column explains how many genes were found 
to be in common among the different experiments’ top differentially expressed genes. 
 
For instance, none of the 21 intersecting genes among the top 35% of differentially expressed genes across all twelve 
GEO experiments relating to Obesity were present in the gold standard Obesity Gene Map list [21]; however, when 
observing the 180 intersecting genes that were found from a larger proportion of the genes in each experiment, there 
were  six  genes  also  present  on  the  gold  standard  list.  Such  a  finding  indicates  that  certain  genes  may  have  been 
overlooked in the past when studying these diseases; further research may focus on the effect and prominence of these 
seemingly “less” differentially expressed genes. 
 
With respect to the genetic factors related to Huntington’s Disease, the automated pipeline found there to be several 
genes that have already been studied in the context of the disease (RALA, CBX5, CALM3, GLG1, GLUL, MAPK8IP1, 
IMMT, MAP3K8, CDKN1A) [22-28]; however, certain genes were also discovered that have not been researched in 
regard to Huntington’s Disease. It has been shown that some of these genes (SCT, LMNB1, IVD) [29-32] have some 
relation  to  certain  neurodegenerative  diseases  or  are  involved  in  pathways  that  are  relevant  to  the  development  of 
Huntington’s Disease. Although the study for which this paper was written did not look into such genes into great detail, 
these findings demonstrate the possibility that this pipeline may be able to propose novel candidates for disease-related 
genes. 
 
A diagram showing the network of interactions of genes related to Huntington’s Disease is shown in Figure 3. For all 
four diseases, the AUROC values for the models constructed using single net structure were much lower than those of 
the multiple experiments. From these numbers, it is easy to see that the integrative approach using multinets provides 
much better predictive models than do the single net structure.  
The model created to represent genetic factors relating to leukemia also resulted in similar findings – several genes 
in this model have already been studied in varying degrees with respect to leukemia (WT1, PDE4DIP, NCAM1, 
AKAP13, SLC35E1, HFE, JUN) [33-42]; however, a few novel genes were also presented in the model (IVD, 
SYNJ2, TTLL3). Again, such findings demonstrate the power of this project’s methods in discovery of novel disease-
specific genes. 
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5  Conclusion 
New methods that this project explored include: 1) automated (rather than manual) mapping of GEO experiments to 
specific diseases and 2) a structure for automated construction of Bayesian networks with respect to analysis of the 
influence of genetic factors on specific diseases 
 
New findings that this project discovered include: 1) the two integrative frameworks presented in this paper can be 
used for discovery of novel disease-related gene candidates, 2) the accuracy of the integrative predictive models is 
generally  greater  once  the  integration  is  performed  in  assignment  step  (multinets  approach)  rather  than  data 
collection step (single net approach), 3) certain genes that may not be as greatly differentially expressed may still 
hold as much predictive power as those genes at the top of the list, and 3)  
 
 
 
 
 
Figure 3: Constructed Bayesian multinet showing the interactions among genes related to Huntington’s Disease and 
controls.
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